The drugmaker expects around 40 per cent US growth in FY27 despite the end of Bosutinib exclusivity, while focusing on complex generics and improving domestic sales productivity
The drugmaker expects around 40 per cent US growth in FY27 despite the end of Bosutinib exclusivity, while focusing on complex generics and improving domestic sales productivity
<iframe src="https://hindustansphere.com/embed/cluster/478b448eb1f45fd16878f205bf716b283fb9f658" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Alembic bets on 30 US drug launches to sustain growth as exclusivity ends"></iframe>
